Chimerix Shares Brain Cancer Trial Data

Chimerix Inc CMRX has reported topline data from its 50-patient efficacy analysis of ONC201 for recurrent H3 K27M-mutant glioma (a most common type of brain cancer).
ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist.
An efficacy analysis by blinded independent central review (BICR) of the registration cohort determined the overall response rate (ORR) to be 20.0%.
The median duration of response was 11.2 months, and the median time to response was 8.3 months.
One serious adverse event was attributed possibly related to ONC201. Full safety data collection and analysis for this cohort is ongoing.
Prior safety review of ONC201 identified the most commonly reported adverse events as nausea/vomiting, fatigue, and decreased lymphocyte counts.
The Company posted a Q3 EPS loss of $(0.21), missing the consensus of $(0.15) and higher than the loss of $(0.18) a year ago.
Chimerix's capital available to fund operations stood at $125 million at the end of Q3.
Price Action: CMRX shares closed up 3.74% at $6.10 on Thursday.